ArticleJournal of cancer research and clinical oncology2007

Low LATS2 mRNA level can predict favorable response to epirubicin plus cyclophosphamide, but not to docetaxel, in breast cancers.

Yuri Takahashi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.